- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Bausch + Lomb names Appio interim CEO as Saunders hits the exit again | ||
| Mo | Invenra deals patient perspectives into the ADC game with custom card deck | ||
| Mo | Asahi Kasei buyout yields novel FDA herpes nod in immunocompromised patients | ||
| Mo | Media OS is designed to tackle healthcare advertising's identity challenge | ||
| Mo | Why Patient Voice Must Shape Pharma Strategy | ||
| Mo | Par Health recalls more IV bags on cellulose risk weeks after similar action | ||
| Mo | UCB's Bimzelx takes top drug ad spending spot as streaming data come to the fore | ||
| Mo | AI, Data and the New Rules of HCP Marketing | ||
| Mo | How Ohio Is Building a Biopharma Growth Engine | ||
| Mo | AI-Powered Brand Sites Are Changing Patient Engagement | ||
| Mo | Why Medical Teams Must Lead DOL Strategy | ||
| Mo | RevHealth's Chris Cullmann on AI and Human-Centered Pharma | ||
| Mo | How Predictive Modeling Uncovers Blind Spots in the Patient Journey | ||
| Mo | Why AI's Biggest Value in Pharma Is Confidence | ||
| Mo | Executive Interviews at Fierce Pharma Week 2026 | ||
| Mo | Fullspan Health on Winning the AI Search Revolution | ||
| Mo | Why AI and Precision Matter in Pharma Commercialization | ||
| Mo | Beyond the Pharmacy Counter: Inmar's Data Advantage | ||
| Mo | Beyond Data: Understanding the "Why" Behind HCP Decisions | ||
| Mo | Why MRC Accreditation Is Just the First Step | ||
| Mo | Why Medical Affairs Is Becoming Biopharma's Third Pillar | ||
| Mo | From Data Rich to Decision Ready in Life Sciences | ||
| 09.10. | GSK commits $800M to R&D, manufacturing hub, as Pennsylvania bonds deepen | ||
| 09.10. | Quince Therapeutics relaunches as IRulya, going all in on lung disease after Hail Mary merger | ||
| 09.10. | FDA's Rasonque review documents pressure RevMed as investors jitter over KRAS subgroup data |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.